Effects of Hypericum perforatum hydroalcoholic extract, hypericin, and hyperforin on cytotoxicity and CYP3A4 mRNA expression in hepatic cell lines: a comparative study

Medicinal Chemistry Research

Volumn 25, Issue 12, 2016, Pages 2999-3010

  Martinho, Ana ^a   Silva, Sara M ^a   Garcia, Sara ^a   Moreno, Ivo ^a   Granadeiro, Luiza Breitenfeld ^a   Alves, Gilberto ^a,b   Duarte, Ana Paula ^a   Domingues, Fernanda ^a   Silvestre, Samuel ^a,b   Gallardo, Eugenia ^a  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

CYP3A4 mRNA expression; Cytotoxic activity; Hepatic cell lines; Hyperforin; Hypericin; Hypericum perforatum; in vitro study

Indexed keywords

CYTOCHROME P450 3A4; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; MESSENGER RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG BINDING SITE; DRUG CONFORMATION; FETUS; HEPARG CELL LINE; HEPG2 CELL LINE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; WRL68 CELL LINE;

EID: 84988613657     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-016-1702-z     Document Type: Article

References (67)

1. Barnes J, Anderson LA, Phillipson JD (2001) St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 53(5):583–600
2. Bilia AR, Gallori S, Vincieri FF (2002) St. John's wort and depression: efficacy, safety and tolerability-an update. Life Sci 70(26):3077–3096
3. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J (2000) Drug interaction of St John's wort with cyclosporin. Lancet 355(9218):1912
4. Cantoni L, Rozio M, Mangolini A, Hauri L, Caccia S (2003) Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse. Toxicol Sci 75(1):25–30
5. Chu V, Einolf HJ, Evers R, Kumar G, Moore D, Ripp S, Silva J, Sinha V, Sinz M, Skerjanec A (2009) In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos 37(7):1339–1354
6. Cui Y, Ang CY, Beger RD, Heinze TM, Hu L, Leakey J (2004) In vitro metabolism of hyperforin in rat liver microsomal systems. Drug Metab Dispos 32(1):28–34
7. Di Carlo G, Borrelli F, Ernst E, Izzo AA (2001) St John's wort: Prozac from the plant kingdom. Trends Pharmacol Sci 22(6):292–297
8. Ding X, Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149–173
9. Ernst E, Rand JI, Barnes J, Stevinson C (1998) Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.). Eur J Clin Pharmacol 54(8):589–594
10. Fasinu P, Bouic PJ, Rosenkranz B (2012) Liver-based in vitro technologies for drug biotransformation studies - a review. Curr Drug Metab 13(2):215–224
11. Fox FE, Niu Z, Tobia A, Rook AH (1998) Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. J Invest Dermatol 111(2):327–332
12. Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, Atienzar FA (2012) Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 28(2):69–87
13. Greeson JM, Sanford B, Monti DA (2001) St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 153(4):402–414
14. Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C (2007) The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 168(1):66–73
15. Gutierrez-Ruiz MC, Bucio L, Souza V, Gomez JJ, Campos C, Carabez A (1994) Expression of some hepatocyte-like functional properties of WRL-68 cells in culture. In Vitro Cell Dev Biol Anim 30A(6):366–371
16. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC (2003) The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 74(6):525–535
17. Hellum BH, Hu Z, Nilsen OG (2007) The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 100(1):23–30
18. Hellum BH, Nilsen OG (2008) In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 102(5):466–475
19. Hokkanen J, Tolonen A, Mattila S, Turpeinen M (2011) Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes. Eur J Pharm Sci 42(3):273–284
20. Hu ZP, Yang XX, Chen X, Cao J, Chan E, Duan W, Huang M, Yu XQ, Wen JY, Zhou SF (2007) A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort. Curr Drug Metab 8(2):157–171
21. Ioannides C (1996) Cytochromes: metabolic and toxicological aspects. Taylor & Francis.
22. Ioannides C (2006) Topics in Xenobiochemistry - Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenebiotica 32(6):451–478
23. Jakovljevic V, Popovic M, Mimica-Dukic N, Sabo A, Gvozdenovic L (2000) Pharmacodynamic study of Hypericum perforatum L. Phytomedicine 7(6):449–453
24. Jarema M (2008) Herbal drug treatment. Neuro Endocrinol Lett 29(Suppl 1):93–104
25. Jennen DG, Magkoufopoulou C, Ketelslegers HB, van Herwijnen MH, Kleinjans JC, van Delft JH (2010) Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci 115(1):66–79
26. Kanebratt KP, Andersson TB (2008) Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36(7):1444–1452
27. Karioti A, Bilia AR (2010) Hypericins as potential leads for new therapeutics. Int J Mol Sci 11(2):562–594
28. Klemow KM, Bartlow A, Crawford J, Kocher N, Shah J and Ritsick M (2011) Medical attributes of St. John's Wort (hypericum perforatum). In: Benzie IFF & Wachtel-Galor S (eds) Herbal medicine: biomolecular and clinical aspects edited, 2nd edn. H Boca Raton (FL).
29. Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, Cui YY, Venkataramanan R (2004) Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 32(5):512–518
30. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102(5):1016–1023
31. Linde K (2009) St. John's wort - an overview. Forsch Komplementmed 16(3):146–155. (2006)
32. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V (2006) Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol 62(3):225–233
33. Mai I, Stormer E, Bauer S, Kruger H, Budde K, Roots I (2003) Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 18(4):819–822
34. Mannu J, Jenardhanan P, Mathur PP (2011) A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs. J Mol Model 17(8):1847–1854
35. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD (2003) Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 290(11):1500–1504
36. Martinho A, Goncalves I, Costa M, Santos CR (2012) Stress and glucocorticoids increase transthyretin expression in rat choroid plexus via mineralocorticoid and glucocorticoid receptors. J Mol Neurosci 48(1):1–13
37. Martinho A, Goncalves I, Santos CR (2013) Glucocorticoids regulate metallothionein-1/2 expression in rat choroid plexus: effects on apoptosis. Mol Cell Biochem 376(1–2):41–51
38. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A (2002) Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 94(16):1247–1249
39. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19(14):1639–1662
40. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785–2791
41. Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B (2006) The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 62(1):29–36
42. Muller WE (2003) Current St John's wort research from mode of action to clinical efficacy. Pharmacol Res 47(2):101–109
43. Nahrstedt A, Butterweck V (1997) Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 30(Suppl 2):129–134
44. Nebert DW, Gonzalez FJ (1987) P450 genes: structure, evolution, and regulation. Annu Rev Biochem 56:945–993
45. Novotna A, Krasulova K, Bartonkova I, Korhonova M, Bachleda P, Anzenbacher P, Dvorak Z (2014) Dual effects of ketoconazole cis-enantiomers on CYP3A4 in human hepatocytes and HepG2 Cells. PLoS One 9(10):e111286
46. Obach RS (2000) Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294(1):88–95
47. Ohno Y, Hisaka A, Suzuki H (2007) General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet 46(8):681–696
48. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612
49. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9):e45
50. Polli JE (2008) In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms. AAPS J 10(2):289–299
51. Portoles A, Terleira A, Calvo A, Martinez I, Resplandy G (2006) Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol 46(10):1188–1194
52. Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29(1–2):413–580
53. Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G (2005) Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 78(1):25–33
54. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH (2000) St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 67(5):451–457
55. Russo E, Scicchitano F, Whalley BJ, Mazzitello C, Ciriaco M, Esposito S, Patane M, Upton R, Pugliese M, Chimirri S, Mammi M, Palleria C, De Sarro G (2014) Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions. Phytother Res 28(5):643–655
56. Schulz HU, Schurer M, Bassler D, Weiser D (2006) Investigation of the effect on photosensitivity following multiple oral dosing of two different hypericum extracts in healthy men. Arzneimittelforschung 56(3):212–221
57. Shahrokh K, Cheatham 3rd TE, Yost GS (2012) Conformational dynamics of CYP3A4 demonstrate the important role of Arg212 coupled with the opening of ingress, egress and solvent channels to dehydrogenation of 4-hydroxy-tamoxifen. Biochim Biophys Acta 1820(10):1605–1617
58. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U (2001) Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 285(15):1978–1986
59. Sinz M, Wallace G, Sahi J (2008) Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J 10(2):391–400
60. Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ (2004) Induction of imatinib metabolism by hypericum perforatum. Blood 104(4):1229–1230
61. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas H (2004) St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 75(4):298–309
62. Venkatakrishnan K, von Moltke LL, Greenblatt DJ (1999) Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol 39(6):567–577
63. Wang XD, Li JL, Lu Y, Chen X, Huang M, Chowbay B, Zhou SF (2007) Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: application to a clinical herb-drug interaction study. J Chromatogr B Analyt Technol Biomed Life Sci 852(1–2):534–544
64. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80(4):1029–1036
65. Xie HG, Kim RB (2005) St John's wort-associated drug interactions: short-term inhibition and long-term induction? Clin Pharmacol Ther 78(1):19–24
66. Zanoli P (2004) Role of hyperforin in the pharmacological activities of St. John's Wort. CNS Drug Rev 10(3):203–218
67. Zhou SF (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9(4):310–322